GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022
December 12, 2022 07:30 ET
|
GT Biopharma, Inc.
Presentation shows the therapeutic potential of combining iPSC-derived CAR NK cells and NK cell engagers to overcome the clinical heterogeneity of AML BRISBANE, CALIFORNIA, Dec. 12, 2022 (GLOBE...
GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 10, 2022 15:15 ET
|
GT Biopharma, Inc.
Poster #1: Tri-specific killer engagers target natural killer cells towards mesotheliomaPoster #2: Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel...
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting
November 03, 2022 09:00 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update
October 31, 2022 17:15 ET
|
GT Biopharma, Inc.
Announced two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)$20.8 million in cash, cash equivalents and short-term investments as of September 30,...
GT Biopharma Announces Adjournment of Special Shareholders Meeting
October 04, 2022 16:10 ET
|
GT Biopharma, Inc.
- Meeting adjourned to October 10, 2022 at 11 a.m. PST- GTB encourages all stockholders of record on August 8, 2022 who have not yet voted- to do so by 11:59 p.m. PST Time on October 9, 2022 ...